First Trust Advisors’s Alder Biopharmaceuticals ALDR Stock Holding History

First Trust Advisors’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-57,228	Closed	-$587K	–	2475
2018 Q4	$587K	Sell	57,228 -219,986	-79%	-$2.82M	﹤0.01%	2075
2018 Q3	$4.62M	Buy	277,214 +185,033	+201%	+$3.34M	0.01%	1190
2018 Q2	$1.46M	Buy	+92,181	New	+$1.4M	﹤0.01%	1775

Other funds holding ALDR

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

First Trust Advisors's ALDR Position: Q1 2019 in Review

First Trust Advisors sold out of Alder Biopharmaceuticals (ALDR) in Q1 2019, closing a stake of 57,228 shares — an estimated $587K sold.

First Trust Advisors first reported a position in ALDR in Q2 2018 and held it in 3 quarters. The position peaked at $4.62M in Q3 2018. 123 funds tracked by Wall St. Rank hold ALDR as of Q1 2019.

First Trust Advisors reported no remaining Alder Biopharmaceuticals position as of Q1 2019 after selling out during the quarter.
First Trust Advisors sold 57,228 Alder Biopharmaceuticals shares in Q1 2019, an estimated $587K.
First Trust Advisors first reported a position in Alder Biopharmaceuticals in Q2 2018 and held it in 3 quarters.
First Trust Advisors's Alder Biopharmaceuticals position peaked at $4.62M in Q3 2018.
123 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q1 2019.

Based on First Trust Advisors's 13F filing for Q1 2019, filed 9 May 2019.